Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab

Summary

The purpose of the EAP is to provide access to hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) patients who may benefit from treatment with narsoplimab based on the medical judgement of their respective physicians.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications